Actavis
Morris Corporate Center III
400 Interpace Parkway
Parippany
New Jersey
07054
United States
Tel: 1-862-261-7000
Website: http://www.actavis.com/
Email: actavis@actavis.com
About Actavis
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.Actavis is the world’s third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Actavis’ global branded pharmaceutical business develops and markets products principally in Urology and Women’s Health, and is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.
"Twice As" Video
"Our Winning Way" Video
413 articles about Actavis
-
Actavis And Medicines360 Announce Publication Of ACCESS IUS Efficacy And Safety Study Of LILETTA (Levonorgestrel-Releasing Intrauterine System) 52 mg in Contraception
4/29/2015
-
Actavis Announces Topline Phase 3 Clinical Trial Results For Single-Dose DALVANCE (Dalbavancin) In The Treatment Of ABSSSI
4/24/2015
-
Actavis Announces Retirement Of Charles M. Mayr
4/21/2015
-
Actavis Announces FDA Approval Of Expanded Label For Botox (Onabotulinumtoxina) For The Treatment Of Upper Limb Spasticity In Adults
4/20/2015
-
Actavis To Host First Quarter 2015 Earnings Conference Call And Webcast
4/16/2015
-
With Ackman's Blessing, Actavis Chairman Joins Zoetis Board
4/14/2015
-
Actavis Owes No Apology for Seeking New Alzheimer's Drug Profits, Says Lawyer
4/14/2015
-
Actavis And Medicines360 Announce U.S. Availability Of LILETTA (levonorgestrel-releasing intrauterine system) 52 Mg To Prevent Pregnancy For Up To Three Years
4/14/2015
-
Actavis And Medicines360 Announce U.S. Availability Of LILETTA (levonorgestrel-Releasing Intrauterine System) 52 Mg To Prevent Pregnancy For Up To Three Years
4/13/2015
-
Actavis Confirms Generic Letairis Patent Challenge
4/6/2015
-
Amneal Signs Deal To Acquire The Generic Business Of Actavis Australia
3/31/2015
-
Actavis Slashing More Than 400 Jobs in New York
3/19/2015
-
Actavis Receives FDA Approval For VIIBRYD (vilazodone HCl) 20mg Once Daily As A Therapeutic Dose
3/17/2015
-
Actavis Completes Allergan Acquisition
3/17/2015
-
Actavis Announces Michael R. Gallagher And Peter J. Mcdonnell To Join Board Of Directors
3/17/2015
-
European Commission (EC) Clears Actavis' Pending Acquisition Of Allergan
3/16/2015
-
Actavis Receives FDA Approval Of SAPHRIS For Pediatric Patients (Age 10-17) For Acute Treatment Of Manic Or Mixed Episodes Of Bipolar I Disorder
3/13/2015
-
Actavis Confirms Appeals Court Grants Injunction Pending Appeal Related To Generic Pulmicort RESPULES
3/13/2015
-
Actavis Announces Closing Of Public Offering Of Senior Notes In Connection With Pending Acquisition Of Allergan
3/12/2015
-
Actavis And Allergan Shareholders Approve Proposals Related To Actavis' Planned Acquisition Of Allergan
3/11/2015